Murphy Polly A.
Known title: DirectorCIK: 0001829248
Murphy Polly A.'s purchase track record
How the stock did after each of Murphy Polly A.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since December 20, 2021
Stock higher 6 months later
67%
3 months: 67%
Median 6-month return
+7.5%
3 months: +24.3%
Beat the S&P 500
33%
median -4.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/18/2025 | AVIR | $25K | +25.6% | +7.5% | +11.9% |
| 11/22/2022 | CELC | $48K | +24.3% | +19.8% | +3.5% |
| 12/20/2021 | AVIR | $103K | -18.9% | -21.8% | -17.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AVIR | ▲ Buy | Option Exercise | 29,600 | $0 | 6/18/2026 | View on chart |
| CELC | ▲ Buy | Grant | 1,530 | $0 | 6/5/2026 | View on chart |
| AVIR | ▲ Buy | Option Exercise | 29,600 | $0 | 6/20/2025 | View on chart |
| AVIR | ▲ Buy | Open Market | 6,100 | $25K | 5/18/2025 | View on chart |
| AVIR | ▲ Buy | Option Exercise | 33,150 | $0 | 6/16/2024 | View on chart |
| CELC | ▲ Buy | Open Market | 5,000 | $48K | 11/22/2022 | View on chart |
| AVIR | ▲ Buy | Open Market | 12,000 | $103K | 12/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Celcuity Shares Fall 17% After REVTORPYK Launch and NDA Filing
Celcuity’s stock fell 17.3% after the company announced the launch of its REVTORPYK product in the U.S. and filed a new drug application. The company also said it will present at the European Society for Medical Oncology congress, adding to the mix of upcoming events. With the price near its 14‑day support level of $87.46 and an RSI of 30.1, the move reflects a short‑term reaction to the news rather than a long‑term trend.
Celcuity Shares Fall 17% After REVTORPYK Launch and NDA Filing. Celcuity’s stock fell 17.3% after the company announced the launch of its REVTORPYK product in the U.S. and filed a new drug application. The company also said it will present at the European Society for Medical Oncology congress, adding to the mix of upcoming events. With the price near its 14‑day support level of $87.46 and an RSI of 30.1, the move reflects a short‑term reaction to the news rather than a long‑term trend.